ArticlePloS one2026
Genetic, clinical, and biochemical profiling of Gilbert syndrome in a Nepali cohort: High prevalence of the UGT1A1 c.-3279T>G polymorphism and correlation with hematological parameters.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGilbert Syndrome (GS) is a common hereditary disorder characterized by intermittent jaundice. The pathogenesis is unconjugated hyperbilirubinemia due to reduced hepatic UDP-glucuronosyltransferase 1A1 (UGT1A1) activity. Its genetic basis relies on c.-3279T > G polymorphism (UGT1A1*60), which reduces gene transcription by approximately 40%, and is highly prevalent in Asian populations.
aimsThis study aimed to profile the genetic, biochemical, and clinical characteristics of individuals with clinical features of GS in Nepal and examine correlations between UGT1A1 genotypes and hematological parameters.
methodsThis study utilized a prospective descriptive design supplemented by a retrospective review of medical records, including 75 patients with isolated unconjugated hyperbilirubinemia. Prospective recruitment and data collection were conducted from July 18, 2025, to November 30, 2025. Medical records from outside facilities were accessed for research purposes from July 18, 2025, to November 30, 2025, covering records dating back to January 1, 2021. Patients underwent ARMS-PCR genetic testing for the UGT1A1 c.-3279T > G variant.Patients with hemolysis or hepatobiliary disease were excluded. Genetic confirmation of GS was based on the presence of the G allele.
resultsMean age of cohort was 28.9 ± 10.4 years (range: 14-55), with a male predominance (69.3%). Genotype distribution revealed 66.7% homozygous mutant (G/G), 29.3% heterozygous (G/T), and 4% wild-type (T/T), yielding a G allele frequency of 81.3%. Mean bilirubin levels showed a genotype-phenotype correlation: G/G (4.3 ± 1.1 mg/dL), G/T (3.2 ± 0.9 mg/dL), and T/T (2.4 ± 0.3 mg/dL). Hematological parameters were within normal reference ranges across all genotypes, confirming the non-hemolytic nature of the condition. No hepatosplenomegaly was detected on ultrasonography.
conclusionThis study demonstrates an exceptionally high prevalence of the UGT1A1*60 G allele among individuals with clinical features of GS in Nepal. These findings reaffirm the benign, non-hemolytic character of GS and underscore the diagnostic and pharmacogenetic utility of UGT1A1 genotyping in the Nepali population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.